Abraham Meizler - Kadimastem Director
| KDST Stock | ILA 485.00 35.00 6.73% |
Director
Mr. Abraham Meizler serves as Director at Kadimastem Ltd since April 29, 2014. His work experience includes the following roles Founder and Chief Executive Officer of Meizler Biopharma S.A., Chairman and Vice PresidentBusiness Development of Meizler UCB Biopharma S.A., Founder and Chief Executive Officer of Advantech Bioscience Pharmaceutical Ltd. He holds a Bachelors degree in Architecture and a MBA degree, both from Fundao Getulio Vargas, Brazil. since 2014.
| Age | 64 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Phone | 972 73 797 1600 |
| Web | https://www.kadimastem.com |
Kadimastem Management Efficiency
The company has return on total asset (ROA) of (0.7485) % which means that it has lost $0.7485 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (7.3543) %, meaning that it generated substantial loss on money invested by shareholders. Kadimastem's management efficiency ratios could be used to measure how well Kadimastem manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Gilead Halevy | Compugen | 51 | |
| Avi Slonim | Bonus Biogroup | 38 | |
| Yair Aharonowitz | Compugen | 73 | |
| Joshua Shemer | Compugen | 63 | |
| Arie Ovadia | Compugen | 67 | |
| Sanford Zweifach | Compugen | 60 | |
| Gil Shapira | Bonus Biogroup | 56 | |
| Rachel Ari | Bonus Biogroup | 55 | |
| Eran Perry | Compugen | N/A | |
| Ruth Arnon | Compugen | 86 | |
| Daniel BenLulu | Bonus Biogroup | 54 | |
| Michal Preminger | Compugen | N/A | |
| Dov Hershberg | Compugen | 74 | |
| JeanPierre Bizzari | Compugen | 64 | |
| Yehuda Reznik | Bonus Biogroup | 68 | |
| Kinneret Savitsky | Compugen | 50 | |
| Batia Avital | Bonus Biogroup | 54 | |
Management Performance
| Return On Equity | -7.35 | |||
| Return On Asset | -0.75 |
Kadimastem Leadership Team
Elected by the shareholders, the Kadimastem's board of directors comprises two types of representatives: Kadimastem inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kadimastem. The board's role is to monitor Kadimastem's management team and ensure that shareholders' interests are well served. Kadimastem's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kadimastem's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Keren Tzlill, External Director | ||
| Yossi Nizhar, Vice President - Finance | ||
| Ilan Hadar, External Director | ||
| Arik Hasson, Exec Devel | ||
| Yossi BenYossef, Honorary Consultant | ||
| Michal Izrael, VP Diseases | ||
| David Sultan, Independent Director | ||
| Asaf Shiloni, Chief Officer | ||
| Michel Revel, Chief Scientific Officer-Services Provider, Director | ||
| Ram Epstein, Chief Executive Officer, Director | ||
| Joseph Eldor, Director | ||
| Michal Harel, Vice President - Research & Development-ALS & Neurodegenerative Diseases | ||
| Pr MD, Chief CoFounder | ||
| Avi Bzura, External Director | ||
| Abraham Meizler, Director | ||
| Adina Makover, External Director | ||
| Yigal Fatran, Director | ||
| Eli Opper, Chairman of the Board | ||
| Ziv Ironi, External Director | ||
| Neta Lavon, Vice President - Operations | ||
| Julien Ruggieri, Director | ||
| Arye Hasson, Executive Vice President-Research & Development | ||
| Yehuda Feinberg, Vice President - Finance |
Kadimastem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kadimastem a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.35 | |||
| Return On Asset | -0.75 | |||
| Current Valuation | 38.77 M | |||
| Shares Outstanding | 35.76 M | |||
| Shares Owned By Insiders | 53.72 % | |||
| Shares Owned By Institutions | 8.31 % | |||
| Price To Earning | (167.60) X | |||
| Price To Book | 5.90 X | |||
| EBITDA | (24.48 M) | |||
| Net Income | (26.27 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kadimastem in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kadimastem's short interest history, or implied volatility extrapolated from Kadimastem options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kadimastem. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Kadimastem Stock analysis
When running Kadimastem's price analysis, check to measure Kadimastem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kadimastem is operating at the current time. Most of Kadimastem's value examination focuses on studying past and present price action to predict the probability of Kadimastem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kadimastem's price. Additionally, you may evaluate how the addition of Kadimastem to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |